Silvia Deaglio Selected Research

Hypoxia (Hypoxemia)

1/2021	Targeting of the A2A adenosine receptor counteracts immunosuppression in vivo in a mouse model of chronic lymphocytic leukemia.
3/2020	Immune Response Dysfunction in Chronic Lymphocytic Leukemia: Dissecting Molecular Mechanisms and Microenvironmental Conditions.
10/2017	Macitentan, a double antagonist of endothelin receptors, efficiently impairs migration and microenvironmental survival signals in chronic lymphocytic leukemia.
11/2016	Adenosine signaling mediates hypoxic responses in the chronic lymphocytic leukemia microenvironment.
1/2009	Regulation of transferrin receptor 2 in human cancer cell lines.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Silvia Deaglio Research Topics

Disease

42	Neoplasms (Cancer) 05/2024 - 04/2003
33	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 10/2023 - 02/2002
8	Melanoma (Melanoma, Malignant) 05/2024 - 01/2016
6	Inflammation (Inflammations) 01/2022 - 03/2009
5	Leukemia 12/2022 - 07/2008
5	Hypoxia (Hypoxemia) 01/2021 - 01/2009
5	Disease Progression 01/2018 - 04/2003
4	Hematologic Neoplasms (Hematological Malignancy) 10/2023 - 01/2013
4	Infections 01/2021 - 07/2008
3	Breast Neoplasms (Breast Cancer) 01/2016 - 05/2002
2	Lung Neoplasms (Lung Cancer) 09/2022 - 01/2019
2	Reperfusion Injury 01/2022 - 01/2021
2	Sepsis (Septicemia) 01/2021 - 01/2020
2	Obesity 01/2021 - 01/2020
2	Lymphoma (Lymphomas) 01/2018 - 08/2012
2	Glioblastoma (Glioblastoma Multiforme) 09/2012 - 04/2010
2	Neuroblastoma 10/2011 - 04/2005
1	Necrosis 04/2024
1	Hypocalcemia 03/2024
1	Pathologic Processes 08/2023
1	Renal Insufficiency (Renal Failure) 01/2023
1	Proteinuria 01/2023
1	Kidney Diseases (Kidney Disease) 01/2023
1	Chronic Renal Insufficiency 01/2023
1	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 12/2022
1	Mesothelioma 09/2022
1	Atypical Hemolytic Uremic Syndrome 01/2022
1	Methylmalonic acidemia with homocystinuria 01/2022
1	Methylmalonic acidemia 01/2022
1	Respiratory Tract Infections (Respiratory Tract Infection) 01/2022
1	Fibrosis (Cirrhosis) 01/2022
1	Hyperhomocysteinemia 01/2022
1	COVID-19 01/2021
1	Chronic Disease (Chronic Diseases) 01/2021
1	Inborn Genetic Diseases (Disease, Hereditary) 01/2021
1	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 01/2021
1	Skin Neoplasms (Skin Cancer) 12/2020
1	Colorectal Neoplasms (Colorectal Cancer) 03/2020

Drug/Important Bio-Agent (IBA)

7	EnzymesIBA 10/2022 - 06/2011
7	NAD (NADH)IBA 10/2022 - 03/2009
7	Adenosine (Adenocard)FDA LinkGeneric 01/2021 - 12/2011
6	LigandsIBA 11/2019 - 03/2003
5	Nicotinamide PhosphoribosyltransferaseIBA 10/2022 - 01/2015
4	CytokinesIBA 04/2018 - 06/2012
4	fludarabineIBA 06/2012 - 12/2010
3	Cell-Free Nucleic AcidsIBA 04/2024 - 01/2021
3	AntibodiesIBA 01/2022 - 04/2005
3	Biomarkers (Surrogate Marker)IBA 01/2021 - 01/2016
3	ElementsIBA 01/2018 - 06/2008
3	NucleosidesIBA 01/2016 - 01/2011
3	Transferrin Receptors (Transferrin Receptor)IBA 04/2010 - 07/2007
2	Proteins (Proteins, Gene)FDA Link 10/2023 - 09/2012
2	Drug CombinationsIBA 10/2023 - 07/2011
2	Immunoglobulin M (IgM)IBA 12/2022 - 04/2005
2	Toll-Like Receptors (Toll-Like Receptor)IBA 12/2022 - 01/2020
2	Growth Hormone-Releasing Hormone (Somatotropin Releasing Hormone)IBA 09/2022 - 01/2019
2	AsbestosIBA 09/2022 - 01/2019
2	AntigensIBA 01/2022 - 01/2017
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2019 - 10/2017
2	Adenosine Triphosphate (ATP)IBA 04/2018 - 01/2018
2	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2018 - 11/2016
2	Niacinamide (Nicotinamide)FDA LinkGeneric 01/2018 - 07/2011
2	Interleukin-10 (Interleukin 10)IBA 11/2016 - 02/2015
2	Messenger RNA (mRNA)IBA 09/2012 - 05/2011
2	Hemoglobins (Hemoglobin)IBA 06/2012 - 09/2007
2	IronIBA 01/2009 - 07/2007
1	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 05/2024
1	Mechanistic Target of Rapamycin Complex 2IBA 05/2024
1	DNA (Deoxyribonucleic Acid)IBA 04/2024
1	Calcium-Sensing ReceptorsIBA 03/2024
1	OT-82IBA 02/2024
1	selinexorIBA 10/2023
1	idelalisibIBA 10/2023
1	Antineoplastic Agents (Antineoplastics)IBA 10/2023
1	CreatinineIBA 01/2023
1	Dronabinol (THC)FDA LinkGeneric 10/2022
1	Cisplatin (Platino)FDA LinkGeneric 09/2022
1	Pemetrexed (MTA)FDA Link 09/2022
1	Vitamin B 12 (Cyanocobalamin)FDA LinkGeneric 01/2022
1	Methionine (L-Methionine)FDA Link 01/2022
1	C-Reactive ProteinIBA 01/2022
1	Receptor Tyrosine Kinase-like Orphan ReceptorsIBA 01/2021
1	Blood Group Antigens (Blood Groups)IBA 01/2021
1	Immunoconjugates (Immunoconjugate)IBA 01/2021
1	HLA Antigens (Human Leukocyte Antigens)IBA 01/2021
1	Cyclin-Dependent Kinase 4IBA 01/2021
1	Heme (Haem)IBA 01/2021
1	Purinergic P1 Receptors (Adenosine Receptor)IBA 01/2021
1	Adenosine DeaminaseIBA 01/2021
1	Protein Serine-Threonine Kinases (Protein-Serine-Threonine Kinase)IBA 12/2020
1	Ascorbic Acid (Vitamin C)FDA LinkGeneric 03/2020
1	Cetuximab (Erbitux)FDA Link 03/2020

Therapy/Procedure

21	Therapeutics 05/2024 - 02/2002
3	Drug Therapy (Chemotherapy) 10/2023 - 04/2003
3	Organ Transplantation 01/2023 - 01/2021
3	Transplantation 01/2023 - 01/2022
2	Liver Transplantation 08/2023 - 01/2022
1	AT protocol 01/2022
1	Precision Medicine 01/2022
1	Immunotherapy 01/2021